Dade improved VRSA test:
This article was originally published in Clinica
Dade Behring has received US FDA 510(k) clearance to market an enhanced version of its automated method for detecting vancomycin-resistant Staphylococcus aureus (VRSA). The Deerfield, Illinois company has developed an improved formulation of vancomycin to detect VRSA on its MicroScan dried gram-positive, overnight, antimicrobial susceptibility test panels. Dade, which has nearly 60 MicroScan panels of tests, with up-to-date antibiotics including overnight, rapid and specialty panels, said it was in the process of incorporating the new formulation of vancomycin into the entire product line of MicroScan dried gram-positive, overnight, panels sold globally. The new formulation is anticipated to be available in all of the existing configurations by the autumn of 2005.